Bristol Myers Squibb Press Releases https://bristolmyers2016ir.q4web.com/generated by Q4Sat, 04 Apr 2026 01:38:37 -0400Copyright Q4 Inc. All rights reserved.Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Yearsb4dc8842-1969-45f0-aa28-90025cb28df9https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Evolves-and-Expands-Standing-in-the-Gaap-to-Advance-More-Equitable-Care-in-Multiple-Myeloma-as-Program-Marks-Ten-Years/default.aspxTue, 31 Mar 2026 06:59:00 -0400Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)b1eacdbf-80e8-4d5a-a0f0-c0572bc49302https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Presents-Positive-Results-from-Phase-3-SCOUT-HCM-Trial-Demonstrating-Efficacy-and-Safety-of-Camzyos-mavacamten-in-Adolescents-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM/default.aspxSun, 29 Mar 2026 11:45:00 -0400Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)df08cb23-9fa6-4afd-9cf9-70f6d3d2efc7https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Open-Label-Outpatient-Switch-Study-Demonstrates-Symptom-Stability-During-Transition-from-Oral-Atypical-Antipsychotics-to-Cobenfy-xanomeline-and-trospium-chloride/default.aspxSat, 28 Mar 2026 07:00:00 -0400Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)a81171e5-8020-41dd-a39e-13708e2ed459https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Reinforces-Leadership-in-oHCM-with-New-Camzyos-mavacamten-Data-at-American-College-of-Cardiology-Annual-Scientific-Session--Expo-2026-ACC-26/default.aspxMon, 23 Mar 2026 06:59:00 -0400Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)04a53447-9865-4180-a84d-461555122035https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Transforms-the-Classical-Hodgkin-Lymphoma-Treatment-Paradigm-with-Expanded-U-S--and-EMA-Approvals-for-Opdivo-nivolumab/default.aspxFri, 20 Mar 2026 16:42:00 -0400Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 20269fa6c7f0-0eb5-45e1-936a-e7fb24f46fa7https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-to-Report-Results-for-First-Quarter-2026-on-April-30-2026/default.aspxThu, 19 Mar 2026 06:59:00 -0400Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma4938abd6-b9aa-4479-8f18-abffd661642chttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Announces-Positive-Phase-3-Results-from-the-SUCCESSOR-2-Study-of-Oral-Mezigdomide-in-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxMon, 09 Mar 2026 06:59:00 -0400U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritise47d97a0-a42f-4928-a921-2973c711d3d6https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/U-S--FDA-Approves-Bristol-Myers-Squibbs-Sotyktu-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis/default.aspxFri, 06 Mar 2026 21:59:00 -0500Bristol Myers Squibb Announces Dividendf02b6476-2950-4454-a52a-15873ac7beadhttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Announces-Dividend/default.aspxMon, 02 Mar 2026 16:16:00 -0500SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer8ca4702e-86e7-46d0-ba9b-74c8360dd3e7https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/SystImmune-and-Bristol-Myers-Squibb-Highlight-Positive-Phase-III-Interim-Topline-Results-for-izalontamab-brengitecan-Iza-bren-in-Previously-Treated-Unresectable-Locally-Advanced-or-Metastatic-Triple-Negative-Breast-Cancer/default.aspxThu, 26 Feb 2026 06:59:00 -0500